At EuroPCR 2025, Dr. Aloke Finn and Prof. Antonio Colombo discussed the under-recognized issue of particulate embolization after drug-coated balloon (DCB) angioplasty.

They clarified its distinction from traditional distal embolization and underscored its iatrogenic nature—originating from the device, not plaque or thrombus. The conversation highlighted that particle size, carrier type, and coating technology, particularly crystalline-like coatings, play key roles in downstream safety.

While not universally problematic, embolization may be relevant for specific patients or devices. They stressed the need to translate preclinical insights into clinical practice and to innovate DCB technologies that balance safety with efficacy.

If you were unable to attend the webinar "Aperto® DCB: A Glimpse of the Future Today,” you can still view the session.

Please click here to access the video.

Thanks to Dr. Kitrou from Patras, Prof. Tozzi from Varese, and Dr. Shahverdyan from Hamburg, you will have the opportunity to:

• Gain a comprehensive overview of the DCB’s role in the Vascular Access landscape today and in the future;
• Receive the latest clinical update on Aperto® and its cost-benefit implications;
• Participate in a practical session with a discussion on challenging cases.